

iVoice's Thomas Pharmaceuticals Ltd. Receives Order From Rite Aid Corporation

Acid + All Product Line To Be Sold in More Than 3,300 Stores of Leading Drug Chain

MATAWAN, N.J.--(BUSINESS WIRE)--July 11, 2006--Thomas Pharmaceuticals Ltd, a wholly owned subsidiary of iVoice, Inc. (OTCBB:IVOI), announced today that it has received from Rite Aid Corporation, one of the nation's leading drugstore chains, a stocking order for its smartly packaged and marketed new upscale antacid tablet product line Acid + All(TM). Acid + All(TM) is changing the over-the-counter pharmaceutical category by offering a highly effective pharmaceutical product within an attractive packaging. The product will be sold in more than 3,300 Rite Aid stores in 27 states using a special display carton developed by Thomas at Rite Aid's request.

"We continue to attract leading independent and major pharmacy chains seeking to offer the Acid + All product line," said Tom Thomas, President and Founder of Thomas Pharmaceuticals Ltd. "This agreement with Rite Aid will significantly broaden our distribution in many of the major markets we target."

Acid + All(TM), the calcium enriched, spearmint-flavored, sugar free tablets that soothe heartburn, acid indigestion and gas is available at independent pharmacies, major drug chains and online retailers or by calling toll-free at 1-888-922-1959. Acid + All(TM) will be available in a sleek, 32-count pillbox and will retail for approximately \$3.89. Thomas Pharmaceuticals Ltd. plans to introduce Acid + All(TM) line extensions later this year along with other new over-the-counter products. For more information about Acid + All(TM) go to www.acidall.com.

About Rite Aid Corporation

Rite Aid Corporation is one of the nation's leading drugstore chains, combining its modern store base, strong brand name, modern distribution centers and superior pharmacy technology with a talented team of approximately 70,000 full and part-time associates serving customers in 27 states and the District of Columbia. Rite Aid currently operates approximately 3,323 stores, reporting total sales of \$17.3 billion at the end of its 2006 fiscal year.

About Thomas Pharmaceuticals Ltd:

Thomas Pharmaceuticals Ltd., based in New York, N.Y., develops and markets over the counter non-prescription healthcare products. The company focuses on high-end, branded consumables. Its first product, Acid + All(TM), is a calcium-enriched, sugar free, anti-gas antacid.

About iVoice, Inc:

iVoice has determined that the best way to create shareholder value, separate and apart from the operating performance of iVoice, is to implement new business opportunities by distributing shares of spin-offs to the company's shareholders. The common stock distributions are part of a broader strategy relating to the transition of iVoice into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors.

Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press

releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.

For more information on iVoice, please visit <http://www.ivoice.com> or <http://www.thomaspharmaceuticals.com/>.

Contact:

CEOcast, Inc. for iVoice
Andrew Hellman, 212-732-4300
adhellman@ceocast.com